Research & Clinical Trials

As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.

| More

NCT01351909

Cyclophosphamide With or Without Veliparib in Patients With Locally Advanced or Metastatic Breast Cancer

Study identifier: NCT01351909
Full study details on clinicaltrials.gov

Name of PARP Inhibitor used in study:

Veliparib (Abbvie)

Eligibility:

  • Phase I: breast cancer that is HER2/neu negative
  • Phase II: ER and PR positive and HER2/neu negative
  • No prior PARP inhibitor treatment (both phases)

Type of study:

Phase I/II study

Treatment:

Participants will be in one of two groups:

  • 21-day cycles with cyclophosphamide and veliparib orally on days 1-21
  • 21-day cycles with cyclophosphamide and a placebo orally on days 1-21

Study sites:

Connecticut
Farmington
University of Connecticut
Contact: Susan H. Tannenbaum 860-679-2474 stannenbaum@uchc.edu

New York
Bronx
Montefiore Medical Center
Contact: Eleni Andreopoulou 718-904-2555 eandreop@montefiore.org

Brooklyn
Maimonides Medical Center
Contact: Susan Burdette-Radoux 718-765-2644 sburdette-radoux@maimonides.org

New York
Columbia University Medical Center
New York, New York, United States, 10032
Contact: Kevin M. Kalinsky 212-305-8615 kk2693@columbia.edu

Mount Sinai Medical Center
Contact: George Raptis 212-241-6631

New York University Langone Medical Center
Contact: Yelena Novik 212-731-5350 yelena.novik@med.nyu.edu

Weill Medical College of Cornell University
Contact: Tessa Cigler 212-821-0644 tec9002@med.cornell.edu

Ohio
Columbus
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Contact: Bhuvaneswari Ramaswamy 614-293-6401 bhuvaneswari.ramaswamy@osumc.edu

Page updated 06/13/13